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The use of chemotherapy with concurrent radiation therapy remains a standard
treatment option for patients with unresectable or resected adenocarcinoma of the
pancreas. This treatment strategy is based in large part on data from serial Gas-
trointestinal Tumor Study Group trials that have included 5-fluorouracil. Unfor-
tunately, the majority of patients continue to succumb to the disease process.
Recently, there has been a resurgence in clinical trials utilizing gemcitabine as a
single agent, in combination chemotherapy regimens, and with concurrent radi-
ation therapy. Use with concurrent radiation therapy is based in part on laboratory
studies investigating mechanisms of radiosensitization and strategies that might
increase the therapeutic index. In the current review, the authors summarize the
preclinical data that support the use of gemcitabine as a radiosensitizing agent and
the clinical trials that have been conducted to date. Issues regarding the use of
gemcitabine in concurrent radiotherapy regimens need to be viewed in the context
of both local and distant disease control, given the radiosensitizing and systemic
activity of this agent. Cancer 2002;95:933– 40. © 2002 American Cancer Society.
DOI 10.1002/cncr.10754
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Drugs that affect nucleoside and nucleotide metabolism are amongthe most effective and most widely used agents to sensitize tumor
cells to radiation treatment (i.e., radiosensitizers). These include flu-
oropyrimidines (e.g., 5-FU) and the thymidine analogs (e.g., bro-
modeoxyuridine [BrdUrd] and iododeoxyuridine [IdUrd]). Among
these, 5-FU remains the predominant agent. The deoxycytidine ana-
log gemcitabine (2,2-difluoro-2-deoxycytidine, or dFdCyd) has re-
cently been shown to be a potent radiosensitizer in preclinical stud-
ies. It has now been approved for clinical use as a single agent and in
combination chemotherapy regimens.
The integration of gemcitabine in chemoradiotherapy regimens is
based on this information and the accepted role of chemotherapy
with concurrent radiation therapy in the management of patients
with pancreatic cancer. This treatment strategy is based in large part
on data from serial GITSG trials that investigated the value of 5-FU
based chemoradiotherapy. A marginal benefit associated with this
therapy has been reported in patients with unresectable disease and
in patients who have undergone surgical resection. Unfortunately, the
annual mortality from pancreatic cancer continues nearly to equal
the annual incidence, and few significant advances have been made
in the nonoperative management of these patients.
Advances in the technical delivery of radiation therapy have fur-
ther stimulated the renewed interest in alternative chemoradiother-
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apy regimens for patients with pancreatic cancer. The
integration of new systemic agents such as gemcitab-
ine with advanced radiation therapy techniques in
combined modality regimens holds great promise.
Preclinical Studies
As an analog of deoxycytidine, gemcitabine closely
resembles cytarabine (ara-C). However, unlike ara-C,
gemcitabine has exhibited activity against solid tu-
mors in several murine tumor models.1 The cytotoxic
5-diphosphate (dFdCDP) and triphosphate (dFdCTP)
forms are produced following initial phosphorylation
by deoxycytidine kinase.2,3 These metabolites interfere
with DNA synthesis through several mechanisms. Re-
duction of deoxyribonucleotide pools occurs following
dFdCDP inhibition of ribonucleotide reductase.4 DNA
polymerases necessary for replication are inhibited by
dFdCTP, which competes with dCTP.5,6 The mono-
phosphate can be incorporated into DNA as well, re-
sulting in termination of DNA elongation and de-
creased fidelity of DNA replication.6 – 8 Several other
“self-potentiating” actions of gemcitabine have been
shown, including the inhibition of dCMP deaminase
activity, resulting in decreased dFdCTP catabolism.9
Investigation of the radiosensitizing potential of
gemcitabine was prompted by the observation that
intracellular changes produced by gemcitabine are
similar to those seen following exposure to fluoropy-
rimidines and thymidine analogs and by recognition
of the activity observed in malignancies in which ra-
diation therapy is commonly used.10 –12 Studies in hu-
man solid tumor cell lines were supported further by
demonstration of at least additive interaction in the
rodent EMT6 tumor cell line.13
In Vitro Studies
In the initial studies using human colorectal carci-
noma cell lines (HT-29), metabolism and cytotoxicity
were investigated in addition to radiosensitization.14
Significant enhancement of radiation-induced cell
killing at both noncytotoxic (10 nM) and cytotoxic (30
nM) concentrations was noted. The importance of the
timing of irradiation prior to or during a 24 hour
exposure to the noncytotoxic concentration was also
studied. There was no evidence of radiosensitization
when the cells were irradiated prior to gemcitabine
exposure, while the greatest enhancement ratio was
observed when cells were incubated for the full 24
hours prior to irradiation. Subsequent studies focused
on short term exposure to higher concentrations,
which would more closely approximate the clinical
administration of once weekly infusions. Radiosensi-
tization equivalent to or greater than that resulting
from a 24 hour continuous incubation with a low
concentration of gemcitabine occurred 24 to 48 hours
after a 2 hour exposure to 100 nM (noncytotoxic) or 3
M (cytotoxic) concentrations. The enhancement ra-
tios were 1.6 and 2.9 24 hours after exposure to these
conditions, respectively.15 Since plasma levels greater
than 10 M can be attained following clinical infu-
sions, these findings suggested that gemcitabine could
be a clinical radiosensitizer.16,17 Additional studies
have revealed that cells derived from pancreatic can-
cer, head and neck cancers, adrenal cancer, and breast
cancer are all sensitized by clinically achievable con-
centrations of gemcitabine.18 –20
The initial efforts to investigate mechanisms of
radiosensitization focused on the mechanisms in-
volved following exposure to other nucleoside ana-
logs. Incorporation of the thymidine analogs (BrdUrd,
IdUrd) into DNA has been associated with increased
induction and decreased rates of repair of radiation
induced DNA damage.21 Studies using similar tech-
niques (pulsed-field gel electrophoresis) have found
no effect on radiation induced DNA damage or repair
following exposure to gemcitabine under conditions
known to produce radiosensitization.15,22 The rela-
tionship between incorporation and radiosensitiza-
tion was studied further by evaluation of the time
course of dFdCTP accumulation and radiosensitiza-
tion during a 24 hour gemcitabine exposure. Evalua-
tion of dFdCTP levels is relevant, since analog incor-
poration is proportional to the level of gemcitabine
triphosphate.6 Accumulation of dFdCTP occurred rap-
idly and plateaued within six hours. Yet maximal ra-
diosensitization did not occur until 16 to 24 hours into
the exposure.18 Furthermore, increasing concentra-
tions of gemcitabine (from 0.1 to 10 M) in a 4 hour
exposure, resulting in a 10-fold increase in concentra-
tion of the triphosphate, resulted in no additional
increase in radiosensitization.14 This, and other evi-
dence, suggests that dFdCTP accumulation is not
closely associated with radiosensitization.
In contrast, data tend to support the hypothesis
that gemcitabine mediated radiosensitization is re-
lated to concurrent disruption of deoxyribonucleotide
pools and redistribution of cells into S phase of the cell
cycle. As noted above, the diphosphate metabolite
inhibits ribonucleotide reductase, with a selective ef-
fect on dATP levels in solid tumors. This dATP pool
depletion after gemcitabine occurs with a time course
that correlates with radiosensitization for both colon
and pancreatic cancer cells.14,18 In addition, the re-
duction in dATP associated with radiosensitization in
the two pancreatic cancer cell lines (to 1 M) was
similar, despite the fact that Panc-1 cells have a 10-
fold higher endogenous dATP level compared to the
BxPC-3 cells. In all cell lines investigated, dATP pool
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depletion is required to obtain sensitization. Taken
together, these data provide compelling evidence for
dATP depletion as the important mediator of radio-
sensitization in these cell lines.
Although dATP pool depletion appears to be nec-
essary, it is not sufficient for sensitization to occur. For
instance, treatment of HT-29 cells with high concen-
trations of gemcitabine for a short time ( 4 hours)
produces only moderate sensitization despite near
maximal depletion of dATP pools. Maximum sensiti-
zation appears to require simultaneous redistribution
into S phase along with dATP pool depletion.23 It has
also been proposed that radiosensitization of log
phase cells occurs via selective sensitization of radio-
resistant S phase cells.24
More recently, the role of apoptosis in gemcitab-
ine mediated radiosensitization has been investigated,
since this mechanism of cell death has been shown to
be the pathway by which the drug exerts its cytotoxic
action.7 Cell lines that differ substantially in their abil-
ity to undergo radiation induced apoptosis were eval-
uated to test the hypothesis that gemcitabine pro-
duced radiosensitization by potentiating preexisting
death pathways. Indeed, radiosensitization of apopto-
tic prone HT-29 cells (enhancement ratio 1.81  0.16)
was accompanied by an increase in apoptosis.25 How-
ever, apoptotic resistant UMSCC-6 cells and A549 cells
were modestly radiosensitized (enhancement ratio
1.47  0.24 and 1.31  0.04, respectively) via a non-
apoptotic mechanism. These findings suggest that al-
though apoptosis can contribute significantly to gem-
citabine mediated radiosensitization, the role of
apoptosis in radiosensitization depends on the cell
line rather than representing a general property of the
drug.
In Vivo Studies
In vivo studies have confirmed radiosensitization by
gemcitabine and provided insight into the timing of
gemcitabine administration, relative to radiation ex-
posure, which may optimize the therapeutic index. In
one study, Milas et al. gave tumor-bearing mice a
single 50 mg/kg intraperitoneal dose of gemcitabine at
various times before or after a single 25 Gy fraction.26
The combination of gemcitabine and radiation re-
sulted in regrowth delays greater than the sum of the
individual treatments when gemcitabine was deliv-
ered 3–96 hours before and 1–24 hours after irradia-
tion. The longest regrowth delays occurred when gem-
citabine was administered 24 – 60 hours prior to
irradiation. It is important to note that a single 5
mg/kg intraperitoneal dose of gemcitabine, which
alone had minimal effect on tumor regrowth, en-
hanced tumor radioresponse.27 This confirms the in
vitro finding that minimally cytotoxic concentrations
of gemcitabine can radiosensitize. Gemcitabine re-
duced the dose of radiation required for tumor cure in
50% of animals (TCD50) at all time intervals, with the
largest effect observed when gemcitabine was deliv-
ered one day before irradiation (TCD50 of 33.8 Gy
compared to 51.9 Gy with radiation alone). Again, this
confirms the in vitro data, in which the maximum
enhancement ratios occurred 24 hours after a brief
exposure to gemcitabine.15
A subsequent study investigated radiosensitiza-
tion of both tumor and normal tissue in vivo in an
attempt to determine timing and frequency of gem-
citabine administration that would optimize the ther-
apeutic index.27 In this study, gemcitabine was given
once prior to a course of fractionated radiation, twice
during the course of irradiation, or daily during irra-
diation (total dose, 25 mg/kg). Tumor regrowth delay
was similar for each schedule of gemcitabine admin-
istration over a range of total radiation doses. How-
ever, the radiosensitizing effect on jejunal mucosa was
dependent on the schedule of gemcitabine admin-
istration. The highest therapeutic gain was achieved
by giving a single dose prior to the start of fractionated
radiotherapy. Similar findings have been observed in
studies of bromodeoxyuridine radiosensitization
based on more rapid elimination of analog in normal
tissues.
We have investigated the therapeutic index by
defining an equitoxic regimen utilizing once weekly or
twice weekly gemcitabine during fractionated radia-
tion, and then using these in murine tumor regrowth
delay studies.28 A once weekly administration was se-
lected, since gemcitabine is generally delivered once
weekly in the clinic. A twice weekly delivery was se-
lected in an attempt to maximize radiosensitization,
given the in vitro data indicating radiosensitization for
only 48 –72 hours following drug exposure. Intraperi-
toneal delivery of 800 mg/kg once weekly with con-
current radiation (27.5 Gy in five daily fractions) re-
sulted in a similar level of normal tissue toxicity when
compared to 100 mg/kg twice weekly during the same
radiation treatment, based on acute lip reaction and
weight loss. Tumors treated with twice weekly gemcit-
abine were significantly smaller than tumors treated
with once weekly drug plus radiation, suggesting a
greater therapeutic index as predicted by the in vitro
studies.
Clinical Trials of Gemcitabine Dose Escalation
The use of gemcitabine with concurrent radiotherapy
may represent an approach to improve the outcome of
pancreatic cancer patients considering these preclin-
ical data and clinical reports indicating that gemcit-
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abine provides a survival advantage over 5-FU in pa-
tients with locally advanced (unresectable) or
metastatic pancreatic cancer.10 It has also been shown
to provide symptomatic relief to patients with meta-
static pancreatic cancer who have failed prior treat-
ment with 5-FU.29
Scalliet et al. conducted one of the earliest clinical
trials utilizing gemcitabine with concurrent radiation
therapy in a Phase II trial in patients with Stage III
nonsmall-cell lung cancer.30 In this trial, a conven-
tional course of radiation therapy (60 Gy in six weeks)
was delivered with a weekly intravenous infusion of
gemcitabine at 1000 mg/m2. The trial was closed after
eight patients were accrued, secondary to unaccept-
able pulmonary toxicity (four of eight patients with
Grade 4/5 pulmonary toxicity). The toxicity was attrib-
uted, in part, to large radiation treatment volumes, but
also provided evidence of substantial normal tissue
radiosensitization. It thus highlighted the need for
Phase I trials to investigate gemcitabine dose escala-
tion with concurrent radiation therapy.
A variety of Phase I studies have now been con-
ducted in patients with pancreatic cancer in an effort
to define a tolerable regimen utilizing radiation ther-
apy with concurrent gemcitabine. Blackstock et al.
have investigated twice-weekly gemcitabine during a
course of conventional radiotherapy (50.4 Gy) in 19
patients in an attempt to maximize radiosensitization
(Fig. 1).31 Both hematologic and gastrointestinal tox-
icity were dose limiting. Hematologic toxicity noted in
this trial at 60 mg/m2 is near the maximum tolerated
dose of 65 mg/m2 when gemcitabine alone is delivered
twice weekly.32 Gastrointestinal toxicity may have
been influenced by the schedule of gemcitabine ad-
ministration, with increased radiosensitization of nor-
mal tissues. However, the inclusion of prophylactic
nodal basins in the treatment volume, resulting in a
large volume of normal tissue irradiated, may have
been a more critical factor. A dose of 40 mg/m2 (Mon-
day and Thursday) concurrent with 50.4 Gy has now
been investigated in a Phase II Cancer and Leukemia
Group B (CALGB) 89805 trial, based on this work.33
The toxicity was judged to be manageable, although
only 26% of patients completed therapy without treat-
ment breaks or dose reductions. The median overall
survival for 38 patients treated on this trial was 7.9
months.
In 1996, multicenter Phase I trials were initiated in
patients with locally advanced unresectable disease or
with potentially resectable disease.34,35 Both trials at-
tempted to determine the maximum tolerable dose of
gemcitabine when delivered once weekly, concurrent
with 50.4 Gy (1.8 Gy fractions; Fig. 2). A margin of 3 cm
around the gross target volume was required for the
initial field (39.6 Gy). This margin was reduced to 2 cm
for the final boost (10.8 Gy). The starting dose of
gemcitabine was 300 mg/m2. Hematologic and gastro-
intestinal toxicity have been found to be dose limiting
at 700 mg/m2. Late toxicity remains a concern, as two
of six patients treated at 600 mg/m2 on the trial for
unresectable tumors developed duodenal strictures
three months within completion, with one requiring a
duodenal stent. Objective partial responses were not
observed at doses ranging from 300 –500 mg/m2. How-
ever, three out of six patients treated with 600 mg/m2
experienced an objective partial response. The final
reports describing these trials have not yet been pub-
lished.
Significant gastrointestinal toxicity was encoun-
tered when weekly gemcitabine was delivered at doses
 400 mg/m2 with concurrent rapid fractionation (30
Gy in three Gy fractions).36 In this study, gemcitabine
was delivered on the Friday prior to initiation of radi-
ation, and continued weekly during and following the
course of radiation (Fig. 3). This schedule was based
on in vivo data indicating more selective tumor radio-
FIGURE 1. Treatment schema utilizing
twice weekly gemcitabine (G) with con-
current radiation therapy, which was
tested further in a Phase II Cancer and
Leukemia Group B trial. Reproduced
with permission from Reference 43.
FIGURE 2. Gemcitabine (G) dose es-
calation schema investigated in patients
with unresectable and potentially resect-
able pancreatic cancer. Reproduced
with permission from Reference 43.
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sensitization with exposure at least 24 hours prior to
radiation.27 The treatment volumes covered the pri-
mary tumor with a 3 to 5 cm margin, as well as porta
hepatis and celiac axis lymph nodes. Field sizes
ranged from 10 cm  10 cm to 15 cm  15 cm, and
certainly may be implicated in the toxicity encoun-
tered. It is unclear if the schedule of gemcitabine
administration influenced toxicity.
In a recent Eastern Cooperative Oncology Group
trial, the use of gemcitabine with concurrent pro-
tracted venous infusion (PVI) 5-FU and radiation ther-
apy was investigated, with weekly gemcitabine doses
ranging from 50 to 100 mg/m2 (Fig. 4).37 The radiation
treatment volume included nodes at risk for occult
metastases. Three of seven patients on the trial expe-
rienced gastrointestinal dose limiting toxicity (DLT) at
low weekly doses of gemcitabine. In two patients, this
occurred following completion of radiotherapy (59.4
Gy in 1.8 Gy fractions). In this trial, therefore, the
delivery of concurrent PVI 5-FU, a relatively high dose
of radiation therapy, and the treatment of volumes
including lymph nodes at risk may have contributed
to the toxicity observed.
Clinical Trials of Radiation Dose Escalation
In each of these above-mentioned trials, the emphasis
was on the delivery of radiotherapy with dose escala-
tion of gemcitabine. An alternative strategy has been
investigated at the University of Michigan using stan-
dard doses of gemcitabine, in light of the clinical ben-
efit associated with its use as a systemic agent.10 The
goal was to maximize systemic drug effect while pro-
viding local control through sensitization of a modest
radiation dose. The use of a standard dose (1000 mg/
m2/wk) is also consistent with our laboratory data that
show maximum radiosensitization when cytotoxic
concentrations of drug are used.18 Considering prior
clinical experience, it was clear that the use of full dose
gemcitabine required reduction and investigation of
the radiation dose and modification of treatment vol-
umes. Radiation dose escalation in this Phase I trial
was achieved by increasing the fraction size, thus
keeping the duration of radiation at three weeks. The
radiation fields were planned with three dimensional
radiation treatment planning (3D RTP) to cover only
the gross tumor volume (i.e., no elective nodal irradi-
ation). Doses in the range of 24 – 42 Gy (1.6 –2.8 Gy
fractions) have been investigated. A second cycle of
gemcitabine alone was intended following a one week
rest (Fig. 5).
Thirty seven patients with unresectable (n  34)
or incompletely resected pancreatic cancer (n  3)
were treated.38 Suspected or confirmed metastatic dis-
ease was identified at the time of enrollment in 14
FIGURE 3. Gemcitabine (G) dose es-
calation schema with concurrent rapid
fractionation. Reproduced with permis-
sion from Reference 43.
FIGURE 4. Gemcitabine (G) dose es-
calation schema investigated in the
Eastern Cooperative Oncology Group,
with concurrent protracted venous infu-
sion 5-fluorouracil (PVI 5-FU) and radia-
tion therapy. Fx: fraction. Reproduced
with permission from Reference 43.
FIGURE 5. Radiation dose escalation
schema with concurrent full dose gem-
citabine (G) investigated at the University
of Michigan. Reproduced with permis-
sion from Reference 43.
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patients. Three patients experienced DLT, two with
Grade 4 vomiting (one at 30 Gy and one at 42 Gy dose
levels), and one with gastric/duodenal ulceration at
the 42 Gy dose level. Thus, at the final planned dose
level of the trial (42 Gy in 2.8 Gy fractions), DLT was
noted in two of six evaluable patients. An additional
patient at this dose level experienced late gastrointes-
tinal toxicity that required surgical repair. The occur-
rence of gastrointestinal DLT in two patients at this
final dose level suggests that further dose escalation
may result in intolerable toxicity. We have elected not
to investigate a higher dose based on this observation
and the potential for late toxicity. The concern for late
toxicity is based on radiobiologic data that indicate an
increased risk for late toxicity as the fraction size in-
creases. Application of the linear quadratic model in-
dicates that 42 Gy in 2.8 Gy fractions is biologically
equivalent (with regard to late effects) to 50.4 Gy in 1.8
Gy fractions, a relatively standard dose and fraction-
ation schedule used in the management of patients
with unresectable pancreatic cancer.
With a median potential followup of 22 months,
local progression was noted in 7 of 37 patients, re-
gional progression in 3 of 37, and distant progression
in 25 of 37. These data represent failure at any site,
rather than the first site of failure. Only one patient
has developed local or regional progression in the
absence of distant progression. This suggests that the
reduction in radiation dose and field size did not
result in excess failures at these sites. Median survival
was 11.6 months (95% confidence interval 9.9 to 19.2
months). The presence of metastatic disease at study
entry did not have a significant impact on survival (P
 .69). This approach is currently being incorporated
into a multi-institutional Phase II trial.
The relative lack of gastrointestinal toxicity in our
experience, using a more conformal approach and
exclusion of prophylactic nodal irradiation, suggests
that the radiation treatment volume is perhaps the
most critical variable influencing gastrointestinal tox-
icity in gemcitabine based chemoradiotherapy regi-
mens.
Radiation Therapy Considerations
Traditional radiotherapy treatment volumes have in-
cluded the primary tumor, as defined by chemother-
apy (CT) and/or surgical clips placed at the time of
surgery, as well as pancreaticoduodenal, porta hepa-
tis, and celiac nodes that may be at risk.39 A margin of
normal tissue around these structures is included as
well, given the uncertainties of target definition and
variation in daily patient setup. As a result, a substan-
tial volume of small bowel is included within the treat-
ment fields. The use of 3D RTP is now becoming more
common and may reduce the toxicity associated
with radiotherapy.40,41 This technology enables more
accurate definition of target volumes, as identified on
a dedicated radiation treatment planning CT scan,
thus limiting the amount of adjacent normal tissue
irradiated. In addition, nonaxial beam arrangements
can be utilized that may permit further reduction in
the radiation dose to normal tissue.42 While the im-
pact of this technology has not been fully assessed at
the present time, 3D RTP may become critically im-
portant as more effective systemic therapies are de-
veloped. In this setting, prophylactic irradiation of
regional nodes may not be required, while accurate
targeting of the gross tumor volume, with a minimal
margin of normal tissue, may be essential to optimize
local control.
The issue of radiation treatment volume needs to
be critically addressed in all chemoradiation studies
utilizing gemcitabine, since it is likely to be a potent
radiosensitizer of normal tissues. Comparison of local
toxicity (both acute and late) between trials of gem-
citabine dose escalation and full dose gemcitabine
with radiation dose escalation may be informative, as
the volumes of normal tissue irradiated (as indicated
by the margins of expansion) are dramatically differ-
ent.
Future Considerations
When considering the therapeutic options for patients
with pancreatic cancer, both locoregional control and
systemic failure must be addressed, particularly in
situations in which the radiosensitizer also has sys-
temic activity as a cytotoxic agent and distant failure is
relevant. This is certainly the case in the setting of
pancreatic cancer, where additional improvements in
local control will not likely result in a survival advan-
tage. However, the need for local control is obvious
and may certainly be augmented by the use of gem-
citabine concurrent with radiation. The radiation dose
escalation trial described above, in which full dose
gemcitabine is delivered, is an example of such con-
sideration. The regimen is also based on available
preclinical data, and may serve as a new paradigm of
regimes using gemcitabine with concurrent radiation
therapy. It is also apparent that radiation treatment
volumes will need to be critically assessed and con-
trolled in subsequent Phase II or Phase III trials. As
these trials are designed, the role of gemcitabine based
chemoradiotherapy regimens in the adjuvant setting
will need to be considered as well.
The sequencing of multimodality therapy in pan-
creatic cancer deserves further study as well. Treat-
ment algorithms generally begin with determination
of resectability followed by surgery in patients who
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appear to have operable disease. Surgical treatment
alone rarely cures patients with this disease. A sub-
stantial fraction of patients are unable to receive post-
operative adjuvant therapy or have treatment delayed
due to postoperative recovery (following resection or
exploration without resection). Preoperative chemora-
diotherapy can shorten the course of treatment and
increase the fraction of patients receiving all modali-
ties of therapy. As distant disease is a component of
failure in a majority of cases, earlier application of
systemic treatment may be a better strategy for con-
trol of micrometastasis. This potential would be max-
imized with the use of chemoradiotherapy regimens
that emphasize the systemic component of therapy.
Preoperative radiotherapy may also be associated with
less toxicity due to radiation treatment volume con-
siderations, since the target remains in situ. Issues of
sequencing must also be considered in patients with
unresectable disease based on imaging, particularly
when the combined modality therapy is designed to
optimize local control. In this setting, delivery of sys-
temic therapy preceding the measures for local con-
trol should be emphasized.
The considerations discussed above may, if ap-
propriately applied, provide some incremental benefit
to patients with pancreatic cancer. The development
of novel agents may improve results as well. As newer
agents are integrated into more conventional com-
bined modality regimes, these considerations become
even more critical, such that the novel agents can be
incorporated to maximize their potential.
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